Selected Publications
Mamtani R, Matsubara N, Pino AM, Herranz UA, Şendur MAN, Gravis G, Huillard O, Lee HJ, Gafanov R, Joly F, Bedke J, Sella A, Chang YH, Imai K, Moreno BH, Xu JZ, Alva A, Powles T.: Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial Clin Genitourin Cancer 23 : 102248,2025.
Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C.: Evolving racial/ethnic disparities in AML survival in the novel therapy era Blood Adv 9 : 533-544,2025.
Stalker M, Qu K, Cohen RB, Mamtani R, Hwang WT, Sun L.: "Off-Label" Use of Checkpoint Inhibitors in Patients With Negative or Unknown PD-L1 Status in Advanced Head and Neck Cancer J Natl Compr Canc Netw : 2025.
Orcutt X, Chen K, Mamtani R, Long Q, Parikh RB.: Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations Nat Med : 2025.
Fléchon A, Morales-Barrera R, Powles T, Alva A, Özgüroğlu M, Csöszi T, Loriot Y, Rodriguez-Vida A, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Gunduz S, Mamtani R, Yu EY, Montesa Pino A, Anido U, Sendur MAN, Gravis G, Révész J, Kostorov V, Huillard O, Ma J, Rajasagi M, Vajdi A, Lunceford J, Cristescu R, Imai K, Homet Moreno B, Matsubara N.: Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma Clin Cancer Res 30 : 5353-5364,2024.
Guadamuz JS, Wang X, Altomare I, Camelo Castillo W, Sarkar S, Mamtani R, Calip GS.: Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer, 2011-2023 JNCI Cancer Spectr 8 (5): 2024.
Barsouk A, Elghawy O, Yang A, Sussman JH, Mamtani R, Mei L: Meta-Analysis of Age, Sex, and Race Disparities in the Era of Contemporary Urothelial Carcinoma Treatment Cancers 16 (19): 2024.
Mamtani R, Ulloa-Pérez E, Parikh RB, Patel K, Homet Moreno B, Ramamurthy C, Li H, Hubbard RA: Real-world Uptake of Enfortumab Vedotin plus Pembrolizumab after US Food and Drug Administration Approval Among Patients with Advanced Urothelial Cancer European Urology 24 : 2024.
Chapin WJ, Hwang WT, Mamtani R, O'Hara MH.: Low- vs High-Dose 5-FU in Triplet Chemotherapy Plus Bevacizumab for Patients With Colorectal Cancer JAMA Netw Open
7 (7): 2024.
Mamtani R, Tsingas K, Parikh RB, Elsouda D, Mucha L, Fuldeore R, Hubbard RA: Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer Urol Oncol 42 (6): 2024.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia,
PA
19147
Phone: 215-662-7606
Patient appointments: 800-789-7366